RxDoctor Payments Data

Jessica Thomas, NP

Adult Health · Harrisonburg, VANPI 1568084556

Payments from drug & device makers

What this record shows

The money is spread across several categories — food and beverage (56.2%), travel and lodging and education — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 61.1% of it on its own, with 7 other manufacturers making up the rest. Reporting peaked in 2023 at $3,133 and has fallen 71.4% since, to $896 in 2025.

$4,677in general payments, 2019–2025

Across 60 payments — averaging $77.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Boston Scientific$3K
  • Medtronic$1K
  • E.r. Squibb & Sons, L.L.C.$141
  • Kiniksa Pharmaceuticals International, PLC$135
  • Pfizer$99
  • Johnson & Johnson$77
  • plus $89 from 2 others

What the payments were for

  • Travel & lodging$2,03744%
  • Food & beverage$2,62756%
  • Education$140%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,677 in reported general payments places this provider in the 85th percentile of 368 adult health providers in Virginia.

See all adult health providers in Virginia

Medicare billing

Part B allowed, 2024
$14,897
Medicare patients
179
Services billed
382

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban141$123,481
Metoprolol Succinate118$1,232
Flecainide Acetate42$1,103
Amiodarone Hcl40$408
SotalolSotalol Hcl24$320
Colchicine11$279
ClopidogrelClopidogrel Bisulfate50$266
Metoprolol Tartrate76$220
Verapamil ErVerapamil Hcl11$182
Losartan Potassium26$161
Lisinopril23$140
Omeprazole23$126
Spironolactone28$92
Amlodipine Besylate12$45
Atorvastatin Calcium14$43

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$99$123,481141 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 368 adult health providers in Virginia.

Other adult health in Harrisonburg

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →